DIN, NPN, or DIN-HM: How to Choose the Right Health Canada Regulatory Pathway

One conversation I have almost every week goes like this: a manufacturer has already locked in their formula, signed a contract manufacturer, maybe even started stability studies — and then they ask whether they need a DIN or an NPN.

That sequencing problem is expensive.

Getting product classification right is the first decision in any Canadian market entry strategy, not an afterthought. And the rules governing it — under Canada’s Natural Health Products Regulations (NHPR) and the Food and Drug Regulations (FDR) — are specific enough that an innocent-sounding label claim can push your product from a 180-day NPN review into a 400-day DIN submission. I’ve seen that derail launch timelines by 18 months. It’s a mistake that’s entirely avoidable.

Here’s what you actually need to understand before you commit to a pathway.

What Separates a DIN from an NPN Under Canada’s Natural Health Products Regulations

A Drug Identification Number (DIN) is issued to pharmaceutical drugs under the Food and Drug Regulations. It covers both prescription and over-the-counter (OTC) products — acetaminophen tablets, antifungal creams, a prescription antibiotic. A Natural Product Number (NPN) is issued under the NHPR, which came into force in January 2004. It applies to vitamins, minerals, herbal remedies, probiotics, amino acids, essential fatty acids, and certain homeopathic preparations diluted beyond a defined threshold.

The single most important distinction between the two: the type of claim you intend to make.

If your product makes a therapeutic claim — treating, mitigating, or curing a named disease or condition — it’s a drug. That means a DIN application through Health Canada’s Health Products and Food Branch, a full Chemistry, Manufacturing and Controls (CMC) package, and, depending on the drug class, clinical evidence that can run into the tens of millions of dollars. Standard review for a new DIN submission takes 300–500 calendar days once you account for deficiency rounds and response timelines. Priority review is available for serious or life-threatening conditions, but that’s a separate discussion.

An NPN product, by contrast, makes claims framed around health maintenance, risk reduction, or symptomatic relief at a population level — not disease treatment. “Supports healthy immune function” is NPN territory. “Treats influenza” is not. The evidence requirements are correspondingly lower, and review timelines for Class I and Class II NPN applications typically run 180 days. Novel or complex Class III submissions — where modern clinical evidence is required — routinely reach 300 days or more. There are currently over 60,000 licensed natural health products on the Canadian market, which gives you some sense of how well-established this pathway is.

One detail that surprises many formulators: it isn’t just the claim language that matters. Ingredient concentration can also change your classification. Melatonin is the clearest example. Products containing melatonin at doses up to 10 mg for sleep support are generally accepted under the NPN pathway. Push into higher-dose formulations with modified-release mechanisms and expanded clinical claims, and Health Canada begins treating the submission as a drug. Same molecule, entirely different regulatory world.

When Does a Homeopathic Product Need a DIN-HM?

The DIN-HM — Drug Identification Number for Homeopathic Medicine — sits within the NPN framework but applies specifically to homeopathic preparations. Under the NHPR, a homeopathic medicine is defined as a preparation that uses dilutions of substances listed in a recognized homeopathic pharmacopoeia; the Homeopathic Pharmacopoeia of the United States (HPUS) and several European compendia are accepted references.

The dilution threshold is specific: to qualify for a DIN-HM, the preparation must generally be diluted to at least 4X or 2C potency. Products below that threshold can be assessed as conventional drugs, triggering the DIN pathway regardless of how the product is labelled.

A DIN-HM application still goes through Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD), and the evidence standard leans heavily on traditional homeopathic use. You’re not expected to submit randomized controlled trials. But you are expected to provide appropriate compendial references, demonstrate the homeopathic rationale, and meet the GMP requirements that apply across all licensed health products in Canada — including site licensing for your manufacturer.

Most companies don’t face a real choice between NPN and DIN-HM; the formula drives the determination. The confusion tends to arise in combination products, where homeopathic ingredients are blended with NHP ingredients such as vitamins or botanicals. Those combination submissions are reviewed under the NPN pathway and must satisfy evidence requirements for each ingredient category present. If a product has both a 6C homeopathic dilution and a standardized herbal extract, the application is an NPN — and the herbal evidence requirements apply in full.

How to Determine Your Pathway Before You Formulate

The most valuable tool Health Canada offers — and the one too few companies use early enough — is the Product Classification Request (PCR). It’s a formal written inquiry to the NNHPD asking Health Canada to classify your product before submission. You provide your intended ingredients with quantitative amounts, dosage form, and proposed label claims. Health Canada provides a written determination.

It costs nothing. It’s not technically binding in every scenario, but in practice it anchors your regulatory strategy and substantially reduces reclassification risk downstream. And it can prevent the most common costly mistake: spending six to nine months developing a submission for the wrong pathway.

To file a useful PCR, you need:

• Full ingredient list with concentrations and dosage form
• All proposed label claims, including any implied by the product name
• The evidence basis you intend to rely on — traditional use or modern clinical
• Intended consumer population

One practical warning: PCR turnaround times typically run 30–60 days, and have stretched longer during periods of high submission volume at NNHPD. Build that window into your development calendar. If you’re working toward a hard launch date, a delayed classification response can compress every downstream step simultaneously.

The alternative — filing without a PCR and making an educated guess — occasionally works. But I’ve seen manufacturers submit a complete NPN application, receive deficiency questions 180 days in, and be told their product requires a DIN. The submission fees and regulatory preparation costs spent on the wrong pathway are non-recoverable. The time is also non-recoverable.

One more classification consideration that trips up international entrants: traditional use evidence has a specific time requirement under the NHPR. To support a traditional use claim, the evidence base must reflect use for at least 50 years, with a minimum of 15 years of documented use in a Western tradition if that’s the tradition being cited. If your product is well-established in an Asian traditional medicine system, Health Canada has specific guidance on which pharmacopoeias and reference texts qualify. Assuming your evidence base transfers automatically from another jurisdiction is a mistake.

Timeline and Cost Realities That Should Drive the Decision

Here’s the practical comparison most regulatory consultants don’t lay out plainly enough:

NPN Class I/II (traditional use): Review target of 180 calendar days. Fees under Health Canada’s cost recovery schedule are relatively modest. GMP compliance required for the licensed site. No clinical studies required for traditional use claims, but the evidence dossier still needs structure, sourcing, and a coherent compendium strategy.

NPN Class III (modern evidence): Review target of 300 calendar days. Requires safety and efficacy studies. Higher evidence burden and more robust CMC requirements. Effectively bridges toward drug-level expectations in terms of evidence rigour.

DIN New Drug Submission: Standard review target of 300 days, realistically 400–500 days with deficiency rounds. Clinical data required. Full CMC package. Considerably higher regulatory investment across legal, scientific, and submission management costs.

DIN-HM: Review target of 180 days for standard applications. Evidence basis is traditional homeopathic use. GMP-compliant site licensing required. Scope is narrower and more contained than a DIN NDS.

The cost differential between a well-assembled NPN dossier and a full DIN New Drug Submission isn’t a rounding error. A competent NPN regulatory program typically runs $30,000–$80,000 CAD including preparation, agency fees, and consulting support. A DIN NDS for a novel drug is a multi-year, multi-million-dollar undertaking. That’s not a reason to misclassify a drug as an NHP — it’s a reason to know exactly which category you’re in before you commit resources.

And if you’re entering Canada from a market where your product is already approved — under an FDA NDC registration in the United States, a CE mark in Europe, or a TGA listing in Australia — don’t assume the Canadian classification follows automatically. Health Canada makes independent determinations. A product classified as a dietary supplement in the US does not automatically qualify as a natural health product in Canada. The natural health products regulations in Canada have their own definitions, evidence standards, and approved claims framework, and Health Canada is not obligated to accept foreign approvals as equivalent.

Don’t Let Post-Approval Claim Drift Undo Your Work

This one catches companies after market entry, and it’s entirely avoidable. A licensed NPN carries specific approved claims. If marketing subsequently shifts the language — on a website, in a retail flyer, in social media copy — to imply disease treatment, that product has effectively migrated into drug territory without a DIN. Health Canada’s market surveillance and inspection program specifically monitors for this. A complaint from a competitor or consumer can trigger a compliance review, and the consequences range from a formal warning letter to a product recall and voluntary withdrawal.

The claims you file are the claims you operate under. If your commercial team wants to evolve the language as the product gains traction in the Canadian market, loop regulatory back into that conversation before anything goes live. Claim migration is one of the more common compliance findings we see in established brands that have been on the market for years without incident — until they aren’t.

Getting the classification right from the start, filing a PCR before formulation is locked, and maintaining discipline around approved claims post-launch are the three habits that separate companies with clean Canadian regulatory records from those managing ongoing compliance issues. None of it is complicated. But all of it requires doing the work in the right order.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• USP Monograph Testing and Raw Material COA Verification — Independent ISO 17025-accredited laboratory testing for supplement ingredients and finished products under FDA and USP frameworks.
• EU Market Entry and Natural Product Regulatory Compliance — Regulatory support for cosmetics and natural product companies entering the European market under EU 1223/2009 and REACH requirements.